Relationship of creatine kinase to body composition, disease state, and longevity in ALS.

Relationship of creatine kinase to body composition, disease state, and longevity in ALS.
复制标题

DOI:
10.3109/21678421.2015.1062516
复制
发表时间:
2015
影响因子:
2.8
通讯作者:
Bromberg MB
Bromberg MB
中科院分区:
医学4区
文献类型:
--
作者:
Gibson SB;Kasarskis EJ;Hu N;Pulst SM;Mendiondo MS;Matthews DE;Mitsumoto H;Tandan R;Simmons Z;Kryscio RJ;Bromberg MB

文献摘要

参考文献

被引文献

相似文献

探讨肌酸激酶(CK)水平是否与肌萎缩侧索硬化(ALS)患者的生存率相关,以及相关性是否独立于其他研究充分的预测因素,如发病部位、性别、年龄、无脂肪肿块、痉挛、痉挛和肌束震颤。我们分析了一项为期48周的非干预性纵向多中心营养研究中80例ALS患者的数据,并进行了长期随访。总体平均CK为214 ± 191.8 U/L(范围:22- 1,992 U/L)。45%的患者至少有一个高CK值(>200 U/L),大约一半的患者保持高CK值,但在研究期间没有趋势。男性和肢体发病与高CK显著相关。在单变量分析中,年龄、生物电阻抗谱(BIS)、无脂肪质量、痉挛和肌束震颤与CK水平无关。CK与肌痉挛有显著相关性(P<0.001)。在生存分析中,当调整发病部位、年龄、种族、性别、BIS无脂肪质量和研究中心时,低CK(≤200 U/L)与较长的总生存期相关(P=0.02)。CK可能是ALS生存的一个有用的标志物,这对临床护理和未来临床试验的设计具有重要意义。
To explore if creatine kinase (CK) levels correlate with survival in amyotrophic lateral sclerosis (ALS), and whether a correlation is independent of other well-studied predictors such as location of onset, gender, age, fat free mass, spasticity, cramps, and fasciculations. We analyzed data from 80 ALS patients from a 48 week non-interventional longitudinal multicenter nutrition study with long term follow-up. The overall mean CK was 214 ± 191.8 U/L (range: 22-1,992 U/L). 45% of patients had at least one high CK value (>200 U/L), and about half maintained a high CK value, but there was no trend over the study period. Male gender and extremity onset were significantly associated with high CK. In univariate analysis, age, bioelectric impedance spectroscopy (BIS) fat free mass, spasticity, and fasciculations were not associated with CK level. There was an association between CK and muscle cramps (P<0.001). In survival analysis, low CK (≤200 U/L) was associated with a longer overall survival (P=0.02), when adjusting for location of onset, age, race, gender, BIS fat free mass, and study site. CK may be a useful marker for ALS survival, which has implications for clinical care and the design of future clinical trials.
DOI: 10.3109/17482968.2010.515225
发表时间: 2011-01-01
影响因子: --
作者:
Kasarskis, Edward J.;Mendiondo, Marta S.;Kryscio, Richard J.
通讯作者: Kryscio, Richard J.
DOI: 10.1007/s10072-003-0158-3
发表时间: 2003-11-01
影响因子: 3.3
作者:
Ilzecka, J;Stelmasiak, Z
通讯作者: Stelmasiak, Z
DOI: 10.1212/wnl.24.5.477
发表时间: 1974-01-01
期刊: NEUROLOGY
影响因子: 9.9
作者:
ACHARI, AN;ANDERSON, MS
通讯作者: ANDERSON, MS
DOI: 10.1001/archneur.1966.00470090093013
发表时间: 1966-01-01
影响因子: --
作者:
DAWSON, DM
通讯作者: DAWSON, DM
DOI: 10.1016/s0022-510x(98)00195-6
发表时间: 1998-10-01
影响因子: 4.4
作者:
Felice, KJ;North, WA
通讯作者: North, WA